17 / 30
*TC3 or IC3: ≥50% of TCs or ≥10% of ICs; TC2/3 or IC2/3: ≥5% of TCs or ICs; TC1/2/3 or IC1/2/3: ≥1% of TCs or ICs;
TC0 and IC0: <1% of TCs and ICs
1. Brahmer, et al. N Engl J Med 2015; 2. Borghaei, et al. N Engl J Med 2015
3. Herbst, et al. Lancet 2015; 4. Barlesi, et al. ESMO 2016
PD-L1 does not predict efficacy
for all immune checkpoint
inhibitors in mNSCLC